Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?
about
Use of the tumor necrosis factor-blockers for Crohn's diseaseUse of thiopurines in inflammatory bowel disease: Safety issues.Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experiencePatient's perspectives important for early anti-tumor necrosis factor treatment in inflammatory bowel disease.Treatment-associated acute myeloid leukemia in a patient with Crohn's disease on 6-mercaptopurine.Host responses to the pathogen Mycobacterium avium subsp. paratuberculosis and beneficial microbes exhibit host sex specificity.Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease.Ulcerative colitis, infliximab, and hepatic epithelioid hemangioendothelioma: who is to blame? Case Report.Gastric ulcers and swollen kidneys: a rare diagnosis complicating Crohn's disease.Effects of the probiotic Lactobacillus animalis in murine Mycobacterium avium subspecies paratuberculosis infection.Postoperative outcome of colectomy for pediatric patients with ulcerative colitis.Emerging drugs for the treatment of ulcerative colitisCurrent Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis.The Interleukin-23 / Interleukin-17 axis in intestinal inflammation.Diagnostic ionizing radiation exposure in a population-based sample of children with inflammatory bowel diseases.Immunosuppressive therapies for inflammatory bowel disease.Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies.Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts.Use of biological molecules in the treatment of inflammatory bowel disease.Practical application of anti-TNF therapy for luminal Crohn's disease.An evidence-based systematic review on medical therapies for inflammatory bowel disease.What's the next best cytokine target in IBD?Radiation exposure in patients with inflammatory bowel disease--primum non nocere?Immunomodulators in inflammatory bowel disease: an emerging role for biologic agents.Targeting TNF-α for the treatment of inflammatory bowel disease.Therapeutic peptides in inflammatory bowel disease.Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events.Monitoring for Extra-Intestinal Cancers in IBD.A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease.Rectal Hodgkin lymphoma in a patient with ulcerative colitis: a case studyPrimary effusion lymphoma-like lymphoma in a patient with inflammatory bowel disease.EBV-associated colonic B-cell lymphoma following treatment with infliximab for IBD: a new problem?Mesentery lymphoma in a patient with Crohn's disease: An extremely rare entity.Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease.Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry.Intestinal and extraintestinal neoplasia in patients with inflammatory bowel disease in a tertiary care hospital.Clinical course of Crohn's disease following treatment of lymphoma.Surveillance for colorectal cancer in patients with inflammatory bowel disease.Mortality in inflammatory bowel disease patients under 65 years of age.Diagnostic pitfalls
P2860
Q27030762-EBC1B160-3F1C-4568-BD4C-2015294E4434Q33621267-2165661D-EC49-4F55-A8D8-5204B0A30841Q33750759-45C62E44-F063-4A9C-8636-E8D2019F0EDDQ33756924-3711E46A-C192-445E-8930-551D08304A71Q34091693-35355B01-3AD0-4294-B202-373E62BE3353Q34106914-A9D57ECE-06D3-4B7F-A7E6-93FA53801C87Q34127277-1883D358-4770-4F15-A954-08D6A83138C8Q34409158-92D1E092-C453-4E70-A1F2-3086F35F3052Q34532608-DDC770A9-169C-4AEA-A438-BA3705B6B5F2Q34550242-7F8D0186-1038-4F69-BD88-F2894350D343Q35059483-6EF4DAEA-168A-4434-B595-A7B08A94526BQ36039436-3447C19A-0569-4227-81BA-37628F9A70DEQ36484383-5F635D89-297E-4470-BF86-7B7FDED618D6Q37163418-D7A9F19D-8718-4EE1-B2CB-DDF167D09108Q37458514-A05DBA81-E03B-4503-996D-794CEC776A7BQ37660661-DC38E386-DA43-4C8E-9766-04E9C2FC1166Q37717996-4C586B01-B0FC-4188-85FE-AF8F28564515Q37781314-196FE6F5-D013-4C7A-B317-8099DC07A345Q37829470-883A0630-FE32-4BC2-81E5-C490EE5865B7Q37845327-2F8B23B2-4B90-4B31-AAB6-7628B67191EFQ37862584-5298E8A0-9FAA-4B40-B318-546DD8EAC704Q38003092-B44EF7E8-B2F8-4ABE-A90E-1F5E14AB3C09Q38029114-51095998-B56C-4E4E-A7FF-4D05BE02C36FQ38113159-49789B48-AB61-4608-8B05-69353E167C5AQ38160905-992AFA12-3077-4B57-AF2E-53899C7E5592Q38180807-E81F42F8-FBE8-4DF4-8DB8-727FDB9BD301Q38394816-825790C8-E24C-4942-8187-BBA816975B47Q38585910-52E4D04D-5690-4D43-9AA0-EE4F67BDC7A3Q40006169-FB33B0C8-F2EA-4E37-A054-D9E1D4AC3692Q40554368-712F40E4-E710-4909-818E-5FCF2711BF38Q41909607-8D96FAE3-3A92-4680-A47E-1B79098EF0BFQ41963904-F8143317-3B82-44F9-A597-52A99A2DC66EQ42175343-A96DDFD8-73B1-4983-8B1E-7AB8E5D7433FQ43132889-9C1ACE3A-21A4-47D5-90E6-6D5BF9FF41A6Q43778384-C2B8D781-029F-4031-BFDB-91BEE5650A3BQ46027321-4E71303C-7D79-4C87-A250-249C26B716DEQ46930899-F1956FD1-46BD-434C-8B9F-C1A727E008E9Q50534656-01104115-F3D7-44A5-B3A8-48FFEA856D04Q53286691-BCB81D10-6008-49FF-8E65-1A1996B288BEQ57832717-259821CC-6355-43FC-9781-B86092A92541
P2860
Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?
@en
type
label
Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?
@en
prefLabel
Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?
@en
P2860
P356
P1476
Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?
@en
P2093
Jennifer L Jones
P2860
P304
P356
10.1002/IBD.20211
P577
2007-10-01T00:00:00Z